Sign in with Google
FDA Review Process (DMF)
Join our community on Telegram!
Join the biggest community of Pharma students and professionals.
What Is FDA Review Process?
The FDA Review Process is the structured scientific and regulatory evaluation conducted by the U.S. Food and Drug Administration to determine whether a drug application meets statutory requirements for safety, efficacy, and quality. This process applies to New Drug Applications, Abbreviated New Drug Applications, and Biologics License Applications. From a Regulatory Affairs perspective, understanding the internal review workflow, timelines, and decision pathways is essential for effective submission strategy and lifecycle management.
Regulatory Framework
Drug application review is governed by the Federal Food, Drug, and Cosmetic Act and the Prescription Drug User Fee Act. Under PDUFA timelines, the FDA commits to reviewing standard applications within ten months and priority applications within six months from the filing date. These timelines begin after the agency determines that the application is sufficiently complete to permit substantive review.
FDA Review Lifecycle Overview
| Stage | Description | Typical Timeline |
|---|---|---|
| Receipt and Filing Review | Administrative completeness check | 60 days |
| Substantive Review | Scientific evaluation by review disciplines | Months 2–9 |
| Mid-Cycle Communication | Sponsor update on major issues | Around Month 5 |
| Late-Cycle Meeting | Discussion of labeling and outstanding deficiencies | Around Month 8 |
| Action Letter Issuance | Approval or Complete Response Letter | By PDUFA goal date |
Filing Review Stage
Within the first 60 days, the FDA conducts a filing review to determine whether the application is sufficiently complete. If acceptable, the application is “filed” and assigned a PDUFA goal date. If deficiencies are significant, the application may receive a Refuse-to-File decision. Regulatory professionals must ensure that all modules of the electronic Common Technical Document are complete and technically validated prior to submission.
Substantive Scientific Review
Once filed, the application is distributed to multidisciplinary review teams within the Center for Drug Evaluation and Research. These teams include medical officers, clinical pharmacologists, statisticians, pharmacologists/toxicologists, chemistry manufacturing and controls reviewers, microbiologists when applicable, and labeling specialists. Each discipline conducts an in-depth evaluation of data submitted in Modules 2 through 5.
Key Review Disciplines
| Discipline | Focus Area |
|---|---|
| Clinical | Safety and efficacy evidence |
| Biostatistics | Statistical integrity and analysis |
| Clinical Pharmacology | PK/PD evaluation and dose justification |
| Nonclinical | Toxicology and safety margins |
| CMC | Manufacturing quality and control systems |
| Labeling | Prescribing information accuracy |
Information Requests and Sponsor Interaction
During review, the FDA may issue Information Requests seeking clarification or additional data. These are typically minor and do not extend the review clock. More substantial deficiencies may lead to major amendments, which can extend the PDUFA goal date by up to three months. Effective and timely responses from the sponsor are critical to maintaining review timelines.
Advisory Committee Involvement
For certain applications involving novel mechanisms, safety concerns, or high public interest, the FDA may convene an advisory committee meeting. External experts provide non-binding recommendations to the agency regarding approvability and risk-benefit assessment.
Facility Inspections
For marketing applications, the FDA conducts Pre-Approval Inspections of manufacturing sites to verify compliance with Good Manufacturing Practice requirements. Clinical site inspections may also occur to verify data integrity and Good Clinical Practice compliance.
Regulatory Outcomes
| FDA Action | Meaning | Sponsor Implication |
|---|---|---|
| Approval | Drug meets statutory requirements | Product may be marketed |
| Complete Response Letter | Deficiencies identified | Additional data or corrective actions required |
| Tentative Approval | Scientific approval but blocked by exclusivity or patent | Marketing delayed |
Complete Response Letters outline specific deficiencies in clinical data, CMC information, labeling, or facility compliance. Sponsors must address each deficiency before resubmission. Resubmissions are classified as Class 1 or Class 2, with review timelines of two or six months respectively.
Risk-Benefit Assessment
The FDA’s ultimate decision is based on a comprehensive risk-benefit evaluation. Reviewers assess whether the demonstrated therapeutic benefits outweigh potential risks under labeled conditions of use. Post-marketing requirements or risk evaluation and mitigation strategies may be imposed when necessary.
Strategic Regulatory Perspective
For Regulatory Affairs professionals, successful navigation of the FDA review process requires proactive communication, high-quality submission strategy, readiness for inspections, and strong cross-functional coordination. In multinational pharmaceutical companies, submission planning begins months in advance with mock audits, gap analyses, and regulatory intelligence assessments to anticipate potential review challenges.
Conclusion
The FDA Review Process is a structured, multidisciplinary evaluation designed to ensure that marketed drugs are safe, effective, and manufactured to high quality standards. Mastery of review timelines, agency interaction protocols, deficiency management, and risk-benefit principles is fundamental for any professional aiming to build a career in global drug regulatory affairs.
